Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 13 10:08AM ET
10.08
Dollar change
+2.39
Percentage change
31.08
%
IndexRUT P/E- EPS (ttm)-2.71 Insider Own32.52% Shs Outstand26.65M Perf Week22.93%
Market Cap333.26M Forward P/E- EPS next Y-2.77 Insider Trans-0.74% Shs Float22.31M Perf Month12.88%
Income-77.22M PEG- EPS next Q-0.68 Inst Own66.12% Short Float9.83% Perf Quarter-16.69%
Sales0.00M P/S- EPS this Y77.69% Inst Trans13.45% Short Ratio7.60 Perf Half Y-27.79%
Book/sh4.99 P/B2.02 EPS next Y-0.04% ROA-60.10% Short Interest2.19M Perf Year-4.18%
Cash/sh5.29 P/C1.90 EPS next 5Y- ROE-74.84% 52W Range7.47 - 22.33 Perf YTD-24.89%
Dividend Est.- P/FCF- EPS past 5Y- ROI-44.60% 52W High-54.86% Beta2.86
Dividend TTM- Quick Ratio9.38 Sales past 5Y19.69% Gross Margin- 52W Low34.94% ATR (14)0.89
Dividend Ex-Date- Current Ratio9.38 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)59.60 Volatility6.89% 8.32%
Employees58 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price22.43
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q-27.58% Payout- Rel Volume45.51 Prev Close7.69
Sales Surprise- EPS Surprise-31.19% Sales Q/Q- EarningsNov 13 BMO Avg Volume288.80K Price10.08
SMA2012.01% SMA509.41% SMA200-22.45% Trades Volume1,873,801 Change31.08%
Date Action Analyst Rating Change Price Target Change
Jun-13-24Initiated Robert W. Baird Outperform $28
Jun-06-24Initiated H.C. Wainwright Buy $22
Nov-28-23Initiated Stifel Buy $20
Nov-28-23Initiated RBC Capital Mkts Outperform $22
Nov-28-23Initiated Leerink Partners Outperform $19
Nov-28-23Initiated JP Morgan Overweight $20
Nov-28-23Initiated Chardan Capital Markets Buy $23
Today 07:30AM
Oct-30-24 06:14AM
Oct-22-24 07:30AM
Sep-05-24 07:30AM
Aug-12-24 07:00AM
11:03AM Loading…
Jul-16-24 11:03AM
Jul-15-24 04:17PM
10:11AM
06:36AM
06:00AM
Jul-11-24 08:00AM
Jul-08-24 07:00AM
May-14-24 12:00PM
09:55AM
May-09-24 07:00AM
07:30AM Loading…
May-07-24 07:30AM
Apr-22-24 07:30AM
Apr-16-24 07:30AM
Mar-13-24 04:22PM
Mar-11-24 07:42AM
07:30AM
Feb-05-24 07:00AM
Jan-03-24 07:00AM
Dec-18-23 07:00AM
Dec-13-23 04:59AM
Dec-11-23 12:05PM
07:00AM
Nov-30-23 08:42AM
Nov-02-23 09:51PM
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Townsend Richard NolanChief Executive OfficerOct 10 '24Option Exercise2.335,00011,650125,695Oct 15 01:45 PM
Townsend Richard NolanChief Executive OfficerOct 10 '24Sale8.105,00040,496120,695Oct 15 01:45 PM
Townsend Richard NolanChief Executive OfficerSep 10 '24Option Exercise2.335,00011,650125,695Sep 11 05:17 PM
Townsend Richard NolanChief Executive OfficerSep 10 '24Sale10.655,00053,274120,695Sep 11 05:17 PM
Richard Nolan TownsendDirectorSep 10 '24Proposed Sale10.7912,500134,875Sep 10 04:39 PM
Townsend Richard NolanChief Executive OfficerAug 12 '24Option Exercise2.335,00011,650125,695Aug 13 06:34 PM
Townsend Richard NolanChief Executive OfficerAug 12 '24Sale11.535,00057,634120,695Aug 13 06:34 PM
Townsend Richard NolanChief Executive OfficerJul 10 '24Option Exercise2.335,00011,650175,695Jul 12 04:55 PM
Townsend Richard NolanChief Executive OfficerJul 11 '24Sale17.0728,031478,409120,695Jul 12 04:55 PM
Townsend Richard NolanChief Executive OfficerJul 10 '24Sale16.5026,969444,979148,726Jul 12 04:55 PM
Townsend Richard NolanChief Executive OfficerJun 10 '24Option Exercise2.335,00011,650175,695Jun 12 05:00 PM
Townsend Richard NolanChief Executive OfficerJun 10 '24Sale17.655,00088,264170,695Jun 12 05:00 PM
Townsend Richard NolanChief Executive OfficerMay 13 '24Option Exercise2.335,00011,650175,695May 14 04:04 PM
Townsend Richard NolanChief Executive OfficerMay 13 '24Sale13.225,00066,093170,695May 14 04:04 PM